 |
|
|
| |
Safety and Efficacy of Dolutegravir (DTG; GSK1349572) in Treatment-Experienced HIV-1 Infected Adolescents: 24-week Results from IMPAACT P1093
|
| |
| |
Reported by Jules Levin
ID Week/IDSA Oct 2-6 2013 San Francisco, CA
ID Week: Dolutegravir Effective at 24 Weeks in Adolescents Replacing Failing Regimen - written by Mark Mascolini - (10/04/13)
Rolando M. Viani1, Nan Zheng2, Carmelita Alvero2, Rohan Hazra3, Ellen O'Gara4, Elizabeth Petzold5, Barb Heckman6, Debra Steimers7, Sherene Min7, Andrew Wiznia8, and the P1093 Team 1University of California San Diego, CA, 2Harvard School of Public Health, MA, 3NICHD, MD, 4NIAID, MD, 5Social & Scientific Systems Inc, NC, 6Frontier Sciences Research Foundation Inc, NY, 7GlaxoSmithKline, NC, 8Jacobi Medical Center, NY, USA
|
| |
|
|
|
|
|
